ARTICLE | Clinical News
Chi-Med's fruquintinib meets in mCRC Phase II
March 31, 2015 1:06 AM UTC
Hutchison China MediTech Ltd. (LSE:HCM) said fruquintinib ( HMPL-013) met the primary endpoint of progression-free survival (PFS) in a Chinese Phase II study to treat metastatic colorectal cancer (mCRC).
Chi-Med said its majority-owned Hutchison MediPharma Ltd. R&D subsidiary is still assessing secondary efficacy endpoints, including objective response rate (ORR), disease control rate and overall survival (OS). ...